Univariate and multivariate analyses of clinicopathological factors associated with recurrence-free survival in pair-matched patients
| Variable . | Favourable . | Unfavourable . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |||
| Pleural invasion | Absent | Present | 3.92 | 2.08–7.37 | <0.001 | 1.58 | 0.75–3.30 | 0.221 |
| Vascular invasion | Absent | Present | 4.05 | 2.24–7.32 | <0.001 | 2.10 | 1.03–4.29 | 0.036 |
| Lymphatic permeation | Absent | Present | 4.59 | 2.56–8.26 | <0.001 | 2.86 | 1.47–5.57 | 0.001 |
| EGFR mutation | Mutant | Wild-type | 1.86 | 1.02–3.38 | 0.040 | 1.63 | 0.89–3.01 | 0.108 |
| Variable . | Favourable . | Unfavourable . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |||
| Pleural invasion | Absent | Present | 3.92 | 2.08–7.37 | <0.001 | 1.58 | 0.75–3.30 | 0.221 |
| Vascular invasion | Absent | Present | 4.05 | 2.24–7.32 | <0.001 | 2.10 | 1.03–4.29 | 0.036 |
| Lymphatic permeation | Absent | Present | 4.59 | 2.56–8.26 | <0.001 | 2.86 | 1.47–5.57 | 0.001 |
| EGFR mutation | Mutant | Wild-type | 1.86 | 1.02–3.38 | 0.040 | 1.63 | 0.89–3.01 | 0.108 |
HR: hazard ratio; CI: confidence interval; EGFR: epidermal growth factor receptor.
Univariate and multivariate analyses of clinicopathological factors associated with recurrence-free survival in pair-matched patients
| Variable . | Favourable . | Unfavourable . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |||
| Pleural invasion | Absent | Present | 3.92 | 2.08–7.37 | <0.001 | 1.58 | 0.75–3.30 | 0.221 |
| Vascular invasion | Absent | Present | 4.05 | 2.24–7.32 | <0.001 | 2.10 | 1.03–4.29 | 0.036 |
| Lymphatic permeation | Absent | Present | 4.59 | 2.56–8.26 | <0.001 | 2.86 | 1.47–5.57 | 0.001 |
| EGFR mutation | Mutant | Wild-type | 1.86 | 1.02–3.38 | 0.040 | 1.63 | 0.89–3.01 | 0.108 |
| Variable . | Favourable . | Unfavourable . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P-value . | HR . | 95% CI . | P-value . | |||
| Pleural invasion | Absent | Present | 3.92 | 2.08–7.37 | <0.001 | 1.58 | 0.75–3.30 | 0.221 |
| Vascular invasion | Absent | Present | 4.05 | 2.24–7.32 | <0.001 | 2.10 | 1.03–4.29 | 0.036 |
| Lymphatic permeation | Absent | Present | 4.59 | 2.56–8.26 | <0.001 | 2.86 | 1.47–5.57 | 0.001 |
| EGFR mutation | Mutant | Wild-type | 1.86 | 1.02–3.38 | 0.040 | 1.63 | 0.89–3.01 | 0.108 |
HR: hazard ratio; CI: confidence interval; EGFR: epidermal growth factor receptor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
